Meeting
2021 ASCO Annual Meeting
First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.
Authors
Frederick Lundry Locke
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Frederick Lundry Locke , Shahbaz Malik , Michael Timothy Tees , Sattva Swarup Neelapu , Leslie Popplewell , Jeremy S. Abramson , Jennifer T. McDevitt , Chu Ri Shin , Eren Demirhan , Cyril Konto , Lazaros J. Lekakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04416984
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2529)
DOI
10.1200/JCO.2021.39.15_suppl.2529
Abstract #
2529
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
First Author: Frederick L. Locke
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2019 ASCO Annual Meeting
ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL).
First Author: Sattva Swarup Neelapu
Poster
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
First Author: Jason Westin